Amneal Pharmaceuticals Stock (NASDAQ: AMRX)

Amneal Pharmaceuticals (NASDAQ:AMRX) Stock, Quote.Headers.trade-ideas

Amneal Pharmaceuticals

Amneal Pharmaceuticals Inc is a global pharmaceutical company operating primarily in the U.S., India, and Ireland. With three reportable segments; Generics, Specialty, and AvKARE - It develop, manufacture, and distribute a diverse portfolio of essential medicines. The Generics segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.

Genetic,Research,And,Biotech,Science,Concept.,Human,Biology,And,Pharmaceutical

Analyst Color

Biotech

Equities

Large Cap

News

Downgrades

Health Care

Price Target

Reiteration

Analyst Ratings

Trading Ideas

General

AMPH

AMRX

PRGO

TEVA

VTRS

JP Morgan assesses the specialty pharma sector, highlighting robust fundamentals and new product excitement. Key focus on Teva, Organon, and Viatris.

JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability

Ozempic weight loss pill

Earnings

Guidance

Legal

Movers

Amneal Pharmaceuticals settles $270 million opioid crisis agreement, offering cash and naloxone spray. Boosted by strong Q1 earnings, the company reaffirms fiscal guidance.

Generic Drugmaker Amneal Announces Over $270M In US Opioid Lawsuit Settlement

Amneal Pharmaceuticals reveals Q4 2023 results with $616.98 million revenue, up 1% YoY. Despite an 8% drop in adjusted EBITDA, the company beats EPS expectations. Co-CEOs anticipate growth in 2024, projecting revenues of $2.55-$2.65 billion and adjusted EPS of $0.53-$0.63.

Why Is Generic Drug-Focused Amneal Pharmaceuticals Stock Trading Lower Friday?

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals Inc

Amneal Pharmaceuticals Q2 2024 Earnings Preview

Here is the next potential market catalyst

Amneal Pharmaceuticals beats top-line and bottom-line estimates; raises FY24 outlook

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Amneal Pharmaceuticals</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/amrx-stock-quote/"><strong>AMRX</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Amneal Pharmaceuticals reported earnings per share of 16 cents. This was above the analyst estimate for EPS of 14 cents.</li><li>The company reported revenue of $701.78 million.</li><li>This was 6.63% better than the analyst estimate for revenue of $658.14 million.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/amrx-stock-earnings-amneal-pharmaceuticals-for-q2-of-2024/">AMRX Stock Earnings: Amneal Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

AMRX Stock Earnings: Amneal Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024

Amneal Pharmaceuticals, Inc. (AMRX) Q2 2024 Earnings Call Transcript

In a report released today, Les Sulewski from Truist Financial maintained a Buy rating on Amneal Pharmaceuticals (AMRX – Research Report). The comp...

Amneal Pharmaceuticals (AMRX) Gets a Buy from Truist Financial

In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Amneal Pharmaceuticals (AMRX – Research Report), with a price ta...

Amneal Pharmaceuticals (AMRX) Gets a Buy from Barclays

Organon downgraded, Amneal upgraded as J.P. Morgan reviews specialty pharma

Amneal raised to neutral by J.P. Morgan amid improved growth

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amneal Pharmaceuticals (AMRX – Research Report), Aura Biosciences...

Analysts Offer Insights on Healthcare Companies: Amneal Pharmaceuticals (AMRX), Aura Biosciences Inc (AURA) and Terns Pharmaceuticals (TERN)

AMCX

AURA

CBAT

CLMT

EMRAF

EVRG

FREY

LEGN

NKLA

PCRX

QTRHF

ROAD

SATS

SLVM

TERN

Press Releases

Amneal Releases 2023 Environmental, Social and Governance Report

Amneal Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar

Kashiv BioSciences Enters into Exclusive Licensing Agreement with Amneal for Commercialization of a Proposed Biosimilar to XOLAIR® (Omalizumab)

Amneal Launches FOCINVEZ™, the First Ready-to-Use Version of Fosaprepitant

Amneal to Report Second Quarter 2024 Results on August 9, 2024

Amneal Receives U.S. FDA Approval for Potassium Phosphates Injection IV Bags

Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson's Disease to Be Launched as CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules

Amneal Reports Second Quarter 2024 Financial Results

Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials

Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administration

Amphastar Pharmaceuticals, Inc. - Common Stock

Amphastar Pharma

Arvinas

Axsome Therapeutics

Belite Bio, Inc - American Depositary Shares

Belite Bio

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Catalent

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

Structure Therapeutics Inc. - American Depositary Shares

Structure Therapeutics

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Harmony Biosciences Holdings, Inc. - Common Stock

Harmony Biosciences

Harrow

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Ligand Pharmaceuticals Incorporated - Common Stock

Ligand Pharmaceuticals

Neumora Therapeutics, Inc. - Common Stock

Neumora Therapeutics

Ocular Therapeutix

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Cassava Sciences

Supernus Pharmaceuticals, Inc. - Common Stock

Supernus Pharmaceuticals

Tilray Brands

Verona Pharma plc - American Depositary Shares

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Amneal Pharmaceuticals

Amneal Pharmaceuticals (AMRX) Forecast

Amneal Pharmaceuticals (NASDAQ:AMRX) Stock, Quote.Headers.trade-ideas